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C-peptideAbstract The present study is conducted to investigate the possible antidiabetic effect of certain
phosphodiesterase inhibitors. Diabetes mellitus was induced in 18 h-fasted male wistar albino rats
by intraperitoneal injection of streptozotocin (STZ) in a single dose (50 mg/kg). Gliclazide (Glcl) as
a reference standard in a dose of 10 mg/kg, sildenaﬁl (Sild) in 3 doses (5, 10, 20 mg/kg) as PDE5
inhibitor and vinpocetine (Vinp) in 3 doses (10, 20, 40 mg/kg) as PDE1 inhibitor were injected intra-
peritoneal daily for 2 weeks. Their effects were assessed at different time intervals namely; 2 h after
ﬁrst dose, 1 week and 2 weeks after drug administration. In the present study, STZ signiﬁcantly ele-
vated serum blood glucose (SBG) level, lowered serum insulin, C-peptide levels and decreased liver
glycogen content (LGC). Glcl signiﬁcantly elevated serum insulin and C-peptide levels accompanied
by reduction in serum glucose level and raised LGC. Vinp and Sild elevated serum insulin, C-pep-
tide levels, LGC and decreased SBG level. The antidiabetic effect of Glcl was signiﬁcantly higher
than that of Vinp or Sild. It could be concluded that Vinp possibly produced its insulin stimulatory
action via inhibition of PDE1 while Sild stimulated insulin secretion through inhibition of PDE5.
The increase in serum C-peptide indicated that Vinp and Sild stimulated synthesis of insulin in
the b-cells and Vinp is more potent than Sild in this respect due to the difference in their mechanism
of action.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.
Open access under CC BY-NC-ND license.1. Introduction
Diabetes mellitus (DM) is a metabolic disorder with chronic
hyperglycemia resulting from defects in insulin secretion, insu-
lin action or both.1 Diabetes mellitus is classiﬁed into 4 subtypes
namely; type 1 diabetes mellitus (T1DM), type 2 diabetes melli-
tus (T2DM), gestational diabetes mellitus (GDM) and other
speciﬁc types.2The pathophysiology of T2DM is primarily
due to insulin impairment accompanied by beta-cell failure
resulting from prolonged and increased secretory demand.3
Table 1 Effect of Glcl, Sild and Vinp individually on SBG level of STZ-induced diabetic rats after 2 h of drug administration.
Drugs and doses Parameters
Serum glucose level
Absolute value €X± S.E. (mg %) % of diabetic control
Normal control (citrate buﬀer) 100.5 ± 4.552 23.67
Diabetic control (streptozotocin 50 mg/kg, I.P.) 424.5* ± 26.13 100
Gliclazide (10 mg/kg, I.P.) 64.86a ± 5.383 15.28
Sildenaﬁl (5 mg/kg, I.P.) 384.7b ± 33.79 90.62
Sildenaﬁl (10 mg/kg, I.P.) 354.5ab ± 25.13 83.51
Sildenaﬁl (20 mg/kg, I.P.) 324.7ab ± 20.25 76.49
Vinpocetine (10 mg/kg, I.P.) 373.4b ± 12.24 87.96
Vinpocetine (20 mg/kg, I.P.) 111.4ac ± 9.065 26.24
Vinpocetine (40 mg/kg, I.P.) 118.3ac ± 8.731 27.86
The number of animals in each group ranges between 6 and 8.
Data are expressed as mean ± S.E.
Statistical analysis was carried out by one way ANOVA followed by Post-test Newman–Keuls multiple comparison test.
* Signiﬁcantly different from normal control at P< 0.05.
a Signiﬁcantly different from diabetic control at P< 0.05.
b Signiﬁcantly different from gliclazide at P< 0.05.
c Signiﬁcantly different from sildenaﬁl (20 mg/kg) at P< 0.05.
Table 2 Effect of Glcl, Sild and Vinp individually on SBG level of STZ-induced diabetic rats after 1 week of daily drug
administration.
Drugs and doses Parameters
Serum glucose level
Absolute value €X± S.E. (mg %) % of diabetic control
Normal control (citrate buﬀer) 95.10 ± 4.781 20.80
Diabetic control (streptozotocin 50 mg/kg, I.P.) 457.2* ± 18.31 100
Gliclazide (10 mg/kg, I.P.) 142.9a ± 10.09 31.25
Sildenaﬁl (5 mg/kg, I.P.) 442.8b ± 26.34 96.85
Sildenaﬁl (10 mg/kg, I.P.) 380.0ab ± 34.30 83.11
Sildenaﬁl (20 mg/kg, I.P.) 141.3a ± 9.525 30.90
Vinpocetine (10 mg/kg, I.P.) 166.5a ± 8.371 36.41
Vinpocetine (20 mg/kg, I.P.) 146.8a ± 12.17 32.1
Vinpocetine (40 mg/kg, I.P.) 138.0a ± 9.862 30.18
The number of animals in each group ranges between 6 and 8.
Data were expressed as mean ± S.E.
Statistical analysis was carried out by one way ANOVA followed by Post-test Newman–Keuls multiple comparison test.
* Signiﬁcantly different from normal control at P< 0.05.
a Signiﬁcantly different from diabetic control at P< 0.05.
b Signiﬁcantly different from gliclazide at P< 0.05.
180 M.E.S. El Sayed et al.The complications of diabetes include cardiovascular dis-
ease, peripheral vascular disease, and cerebrovascular disease.4
Moreover, there is a relation between diabetes and growing
different types of cancer.5 The commonly used classes for man-
agement of diabetes have adverse effects such as increased risk
of hypoglycemia, gastrointestinal problems, heart failure6 and
vomiting leading to their incompliance.7
Consequently, it deemed of importance to seek for antidia-
betic drugs with more efﬁcacy and less side effects.
Vinpocetine (Vinp) is a classic PDE1 inhibitor which ele-
vates intracellular levels of cGMP and cAMP.8 Vinp blocks
voltage dependent Ca2+/Na+ channel.9,10 Vinp is a cerebral
vasodilator commonly used in ischemic stroke.11 While
sildenaﬁl (Sild) is a selective PDE5 inhibitor which elevatesintracellular level of cGMP, commonly used in erectile
dysfunction.12 Vinp and Sild show antioxidant activity13–15
which are expected to have potential effects on carbohydrate
metabolism.
The aim of the present study is to investigate the beneﬁcial
effects of PDEIs on DM.2. Materials and methods
2.1. Animals
Adult male wistar albino rats weighing 200–250 g were used.
They were obtained from animal house of Faculty of
Table 3 Effect of Glcl, Sild and Vinp individually on SBG level of STZ-induced diabetic rats after 2 weeks of daily drug
administration.
Drugs and doses Parameters
Serum glucose level
Absolute value €X± S.E. (mg %) % of diabetic control
Normal control (citrate buﬀer) 78.56 ± 4.747 16.74
Diabetic control (streptozotocin 50 mg/kg, I.P.) 469.3*± 46.00 100
Gliclazide (10 mg/kg, I.P.) 72.29 a ± 5.415 15.40
Sildenaﬁl (5 mg/kg, I.P.) 99.56 a ± 3.241 21.21
Sildenaﬁl (10 mg/kg, I.P.) 92.88 a ± 7.286 19.79
Sildenaﬁl (20 mg/kg, I.P.) 111.1 a ± 5.851 23.67
Vinpocetine (10 mg/kg, I.P.) 136.4 a ± 14.59 29.06
Vinpocetine (20 mg/kg, I.P.) 105.0 a ± 3.416 28.43
Vinpocetine (40 mg/kg, I.P.) 111.8 a ± 5.375 23.82
The number of animals in each group ranges between 6and 8.
Data were expressed as mean ± S.E.
Statistical analysis was carried out by one way ANOVA followed by Post-test Newman–Keuls multiple comparison test.
* Signiﬁcantly different from normal control at P< 0.05.
a Signiﬁcantly different from diabetic control at P< 0.05.
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kept in plastic cages and allowed to accommodate for one
week before being subjected to experimentation. They were
fed purina-chew, water was allowed ad libitum. The study
was conducted in accordance with ethical procedures and pol-
icies approved by the ethics committee of Faculty of Phar-
macy, Cairo University.
2.2. Drugs and chemicals
Glcl powder was supplied as a gift from Memphis Pharmaceu-
tical and Chemical Industries, Egypt. Vinp and Sild powders
were supplied as a gift from Global Napi pharmaceuticals,
Egypt. STZ was purchased from Sigma–Aldrich, USA. Glu-
cose kit was purchased from Vitro Scient, Egypt. Rat insulin
ELISA Kit was purchased from ALPCO, USA while Rat C-
peptide ELISA kit was purchased from Wako chemicals,
USA. Glycogen standard powder was obtained from Merck
Darmstadt, Germany. Any other analytical chemicals are of
equal quality or A.R. quality.
2.3. Induction of diabetes mellitus
Diabetes mellitus was induced by STZ in a single dose of
50 mg/kg, I.P. in rats fasted for 18 h.16 STZ was freshly pre-
pared in 0.01 m citrate buffer at pH 4.5.17 In the ﬁrst day of
injection of STZ, 5% oral glucose had been given to the rats
to overcome STZ-induced hypoglycemia.18 On the third day
of STZ injection, the diabetic rats with blood glucose more
than 150 mg/dl were elected.
2.4. Preparation of samples
Blood samples were collected from all groups at 2 h after ﬁrst
dose, 1 week, and 2 weeks of daily drug administration. Blood
samples were withdrawn from the retro-orbital sinus of ani-
mals fasted for 12 h. Blood samples were centrifuged for15 min at 6000 rpm to separate serum to investigate SBG level,
serum C-peptide & serum insulin level. After 2 weeks, the ani-
mals were sacriﬁced by cervical dislocation and the liver was
rapidly isolated for determination of LGC.
2.5. Experimental design
Rats were randomly divided into 9 groups: group 1 received
citrate buffer used as normal control, group 2 received STZ
(50 mg/kg, I.P.) used as diabetic control, group 3 received Glcl
(10 mg/kg, I.P.) used as reference standard, groups 4, 5, 6
received Sild in doses 5, 10, 20 mg/kg, I.P. respectively, and
groups 7, 8, 9 received Vinp in doses 10, 20, 40 mg/kg, I.P.
respectively.
2.6. Determination of biochemical parameters
SBG level was determined according to enzymatic method
described by Tinder.19 High amount of sodium ﬂuoride was
added to the serum before determination of serum glucose
level for extensive inhibition of glycolysis.20 Serum insulin
and C-peptide levels were measured by enzyme-linked immu-
nosorbent assay (ELISA) which is based on the sandwich prin-
ciple using kits (ALPCO, USA) and (Wako chemicals, USA),
respectively. LGC was determined according to the method
described by Kemp and Adrienne.21
2.7. Statistical analysis
Data were expressed as mean ± standard error (S.E.). Statisti-
cal analysis was carried out by one way analysis of variance
(ANOVA) followed by Post-test Newman–Keuls multiple
comparison test for comparisons of means of different groups
using the Graph Pad Prism 5 Program. For all statistical tests,
the level of signiﬁcance was at P< 0.05. Graphical representa-
tions were designed by the Graph Pad Prism 5 program Tables
1–10.
Table 4 Effect of Glcl, Sild and Vinp individually on serum insulin level of STZ-induced diabetic rats after 2 h of drug administration.
Drugs and doses Parameters
Serum insulin level
Absolute value €X± S.E. (lIU/mL) % of diabetic control
Normal control (citrate buﬀer) 9.550 ± 0.27 764
Diabetic control (streptozotocin 50 mg/kg, I.P.) 1.250 * ± 0.08 100
Gliclazide (10 mg/kg, I.P.) 52.67 *a ± 2.30 4205
Sildenaﬁl (5 mg/kg, I.P.) 10.30ab ± 0.34 824
Sildenaﬁl (10 mg/kg, I.P.) 12.02 ab ± 0.36 961.6
Sildenaﬁl (20 mg/kg, I.P.) 17.60 *ab ± 0.58 1408
Vinpocetine (10 mg/kg, I.P.) 20.94 *abc ± 0.37 1675.2
Vinpocetine (20 mg/kg, I.P.) 26.48*abc ± 0.88 2118.4
Vinpocetine (40 mg/kg, I.P.) 37.98 *abc ± 1.31 3038.4
The number of animals in each group ranges between 6 and 8.
Data were expressed as mean ± S.E.
Statistical analysis was carried out by one way ANOVA followed by Post-test Newman–Keuls multiple comparison test.
* Signiﬁcantly different from normal control at P< 0.05.
a Signiﬁcantly different from diabetic control at P< 0.05.
b Signiﬁcantly different from gliclazide at P< 0.05.
c Signiﬁcantly different from sildenaﬁl (20 mg/kg) at P< 0.05.
Table 5 Effect of Glcl, Sild and Vinp individually on serum insulin level of STZ-induced diabetic rats after 1 week of daily drug
administration.
Drugs and doses Parameters
Serum insulin level
Absolute value €X± S.E. (lIU/mL) % of diabetic control
Normal control (citrate buﬀer) 9.30 ± 0.223 502.7
Diabetic control (streptozotocin 50 mg/kg, I.P.) 1.850* ± 0.178 100
Gliclazide (10 mg/kg, I.P.) 22.67 *a ± 0.632 1225.4
Sildenaﬁl (5 mg/kg, I.P.) 3.77*ab ± 0.161 203.78
Sildenaﬁl (10 mg/kg, I.P.) 4.22*ab ± 0.364 228.1
Sildenaﬁl (20 mg/kg, I.P.) 7.40*ab ± 0.258 400
Vinpocetine (10 mg/kg, I.P.) 9.550 abc ± 0.197 516.2
Vinpocetine (20 mg/kg, I.P.) 11.41 *abc ± 0.201 616.75
Vinpocetine (40 mg/kg, I.P.) 13.58 *abc ± 0.197 734
The number of animals in each group ranges between 6 and 8.
Data were expressed as mean ± S.E.
Statistical analysis was carried out by one way ANOVA followed by Post-test Newman–Keuls multiple comparison test.
* Signiﬁcantly different from normal control at P< 0.05.
a Signiﬁcantly different from diabetic control at P< 0.05.
b Signiﬁcantly different from gliclazide at P< 0.05.
c Signiﬁcantly different from sildenaﬁl (20 mg/kg) at P< 0.05.
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3.1. Effect of Glcl, Sild or Vinp on SBG level of STZ-induced
diabetic rats after 2 h of ﬁrst dose, 1 week and 2 weeks of daily
drug administration
STZ signiﬁcantly raised SBG level 4 times that of the normal
control. Glcl (10 mg/kg), signiﬁcantly decreased SBG level to
15.28%, 31.25%, 15.40% of diabetic control after 2 h, 1 week,
two weeks of daily drug administration respectively. Sild
(10 mg/kg) signiﬁcantly lowered SBG level to 83.51%,
83.11%, 19.79% of diabetic control after 2 h, 1 week, 2 weeksof daily drug administration respectively. While, a higher dose
(20 mg/kg) signiﬁcantly lowered SBG level to 76.49%, 30.90%,
23.67% of diabetic control after 2 h, 1 week, 2 weeks of daily
drug administration respectively. The lowest dose of sildenaﬁl
(5 mg/kg) signiﬁcantly reduced SBG level to 21.21% of dia-
betic control on the second week of daily drug administration.
Vinp (20 mg/kg) signiﬁcantly lowered SBG level to
26.24%, 32.1%, 28.43% after 2 h, 1 week, 2 weeks of daily
drug administration respectively. However, the highest dose
(40 mg/kg) signiﬁcantly reduced SBG level to 27.86%,
30.18%, 23.82% after 2 h, 1 week, 2 weeks of daily drug
administration respectively. The lowest dose of Vinp
(10 mg/kg) signiﬁcantly decreased SBG level on the ﬁrst
Table 6 Effect of Glcl, Sild and Vinp individually on serum insulin level of STZ-induced diabetic rats after two weeks of daily drug
administration.
Drugs and doses Parameters
Serum insulin level
Absolute value €X± S.E. (lIU/mL) % of diabetic control
Normal control (citrate buﬀer) 6.050 ± 0.84 307.6
Diabetic control (streptozotocin 50 mg/kg, I.P.) 1.967* ± 0.17 100
Gliclazide (10 mg/kg, I.P.) 35.61*a ± 1.50 1810.4
Sildenaﬁl (5 mg/kg, I.P.) 7.54ab ± 0.181 383.73
Sildenaﬁl (10 mg/kg, I.P.) 9.22*ab ± 0.138 468.73
Sildenaﬁl (20 mg/kg, I.P.) 11.28*ab ± 0.32 573.46
Vinpocetine (10 mg/kg, I.P.) 12.95*ab ± 0.11 658.36
Vinpocetine (20 mg/kg, I.P.) 15.37*abc ± 0.36 781.4
Vinpocetine (40 mg/kg, I.P.) 19.27*abc ± 0.49 979.66
The number of animals in each group ranges between 6 and 8.
Data were expressed as mean ± S.E.
Statistical analysis was carried out by one way ANOVA followed by Post-test Newman–Keuls multiple comparison test.
* Signiﬁcantly different from normal control at P< 0.05.
a Signiﬁcantly different from diabetic control at P< 0.05.
b Signiﬁcantly different from gliclazide at P< 0.05.
c Signiﬁcantly different from sildenaﬁl (20 mg/kg) at P< 0.05.
Table 7 Effect of Glcl, Sild and Vinp individually on serum C-peptide level of STZ-induced diabetic rats after two hours of drug
administration.
Drugs and doses Parameters
Serum C-peptide level
Absolute value €X± S.E. (ng/ml) % of diabetic control
Normal control (citrate buﬀer) 1.633 ± 0.111 384.23
Diabetic control (streptozotocin 50 mg/kg, I.P.) 0.425* ± 0.025 100
Gliclazide (10 mg/kg, I.P.) 13.47 *a ± 0.192 3169
Sildenaﬁl (5 mg/kg, I.P.) 1.755 ab ± 0.024 412.94
Sildenaﬁl (10 mg/kg, I.P.) 2.183 ab ± 0.134 513.64
Sildenaﬁl (20 mg/kg, I.P.) 3.267 *ab ± 0.128 768.7
Vinpocetine (10 mg/kg, I.P.) 3.968 *abc ± 0.104 933.64
Vinpocetine (20 mg/kg, I.P.) 5.090*abc ± 0.169 1197.64
Vinpocetine (40 mg/kg, I.P.) 8.592 *abc ± 0.365 2021.64
The number of animals in each group ranges between 6 and 8.
Data were expressed as mean ± S.E.
Statistical analysis was carried out by one way ANOVA followed by Post-test Newman–Keuls multiple comparison test.
* Signiﬁcantly different from normal control at P< 0.05.
a Signiﬁcantly different from diabetic control at P< 0.05.
b Signiﬁcantly different from gliclazide at P< 0.05.
c Signiﬁcantly different from sildenaﬁl (20 mg/kg) at P< 0.05.
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respectively (Fig. 1).
3.2. Effect of Glcl, Sild or Vinp on serum insulin level of
STZ-induced diabetic rats after 2 h of ﬁrst dose, one week
and two weeks of daily drug administration
STZ signiﬁcantly reduced serum insulin level to nearly 10% of
the normal control value. Glcl (10 mg/kg) signiﬁcantly raised
serum insulin level to 4205%, 1225.4%, 1810.4% of diabetic
control after 2 h, 1 week, 2 weeks of daily drug administration
respectively. The lowest dose of Sild (5 mk/kg) signiﬁcantly
increased serum insulin level to 824%, 203.78%, 383.73% ofdiabetic control after 2 h, 1 week, 2 weeks of daily drug admin-
istration respectively. However, Sild (10 mg/kg) signiﬁcantly
elevated serum insulin level to 961.6%, 228.1%, 468.73% of
diabetic control after 2 h, 1 week, 2 weeks of daily drug admin-
istration respectively however a dose of 20 mg/kg signiﬁcantly
raised serum insulin level to 1408%, 400%, 573.46% of dia-
betic control after 2 h, 1 week, 2 weeks of daily drug adminis-
tration respectively.
The lowest dose of Vinp (10 mg/kg) increased serum insulin
level to 1675.2%, 516.2%, 658.36% after 2 h, 1 week, 2 weeks
of daily drug administration respectively. While, a dose of
(20 mg/kg) raised serum insulin level to 2118.4%, 616.75%,
781.4% after 2 h, 1 week, 2 weeks of daily drug administration
Table 8 Effect of Glcl, Sild and Vinp individually on serum C-peptide level of STZ-induced diabetic rats after one week of daily drug
administration.
Drugs and doses Parameters
Serum C-peptide level
Absolute value €X± S.E. (ng/ml) % of diabetic control
Normal control (citrate buﬀer) 1.683 ± 0.130 426
Diabetic control (streptozotocin 50 mg/kg, I.P.) 0.395* ± 0.051 100
Gliclazide (10 mg/kg, I.P.) 4.685*a ± 0.209 1186
Sildenaﬁl (5 mg/kg, I.P.) 0.773*ab ± 0.048 195.7
Sildenaﬁl (10 mg/kg, I.P.) 0.956*ab ± 0.074 242
Sildenaﬁl (20 mg/kg, I.P.) 1.488ab ± 0.050 367.7
Vinpocetine (10 mg/kg, I.P.) 1.935abc ± 0.052 490
Vinpocetine (20 mg/kg, I.P.) 2.345*abc ± 0.046 593.6
Vinpocetine (40 mg/kg, I.P.) 2.975*abc ± 0.124 753.16
The number of animals in each group ranges between 6 and 8.
Data were expressed as mean ± S.E.
Statistical analysis was carried out by one way ANOVA followed by Post-test Newman–Keuls multiple comparison test.
* Signiﬁcantly different from normal control at P< 0.05.
a Signiﬁcantly different from diabetic control at P< 0.05.
b Signiﬁcantly different from gliclazide at P< 0.05.
c Signiﬁcantly different from sildenaﬁl (20 mg/kg) at P< 0.05.
Table 9 Effect of Glcl, Sild and Vinp individually on serum C-peptide level of STZ-induced diabetic rats after two weeks of daily drug
administration.
Drugs and doses Parameters
Serum C-peptide level
Absolute value €X± S.E. (ng/ml) % of Diabetic control
Normal control (citrate buﬀer) 1.647 ± 0.092 256
Diabetic control (streptozotocin 50 mg/kg, I.P.) *0.6433 ± 0.053 100
Gliclazide (10 mg/kg, I.P.) *a9.278 ± 0.549 1442
Sildenaﬁl (5 mg/kg, I.P.) *ab2.467 ± 0.124 383.67
Sildenaﬁl (10 mg/kg, I.P.) *ab3.068 ± 0.045 477.13
Sildenaﬁl (20 mg/kg, I.P.) *ab3.772 ± 0.105 586.62
Vinpocetine (10 mg/kg, I.P.) *abc4.402 ± 0.106 684.28
Vinpocetine (20 mg/kg, I.P.) *abc5.093 ± 0.126 792
Vinpocetine (40 mg/kg, I.P.) *abc6.452 ± 0.182 1003.42
The number of animals in each group ranges between 6 and 8.
Data were expressed as mean ± S.E.
Statistical analysis was carried out by one way ANOVA followed by Post-test Newman–Keuls multiple comparison test.
* Signiﬁcantly different from normal control at P< 0.05.
a Signiﬁcantly different from diabetic control at P< 0.05.
b Signiﬁcantly different from gliclazide at P< 0.05.
c Signiﬁcantly different from sildenaﬁl (20 mg/kg) at P< 0.05.
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serum insulin level to 3038.4%, 734%, 979.66% after 2 h,
1 week, 2 weeks of daily drug administration respectively
(Fig. 2).
3.3. Effect of Glcl, Sild or Vinp on serum C-peptide level
of STZ-induced diabetic rats after 2 h of ﬁrst dose, 1 week
and 2 weeks of daily drug administration
STZ signiﬁcantly reduced serum insulin level to 25% of the
normal control value. Glcl (10 mg/kg) signiﬁcantly elevated
serum C-peptide level to 3169%, 1186%, 1442% of diabeticcontrol after 2 h, 1 week, 2 weeks of daily drug administration
respectively. Sild (5 mg/kg) raised serum C-peptide level to
412.9%, 195.7%, 383.6% of diabetic control after 2 h, 1 week,
2 weeks of daily drug administration respectively. Sild (10 mg/
kg) elevated serum C-peptide level to 513.6%, 242%, 477.1%
of diabetic control after 2 h, 1 week, 2 weeks of daily drug
administration respectively. A higher dose of Sild (20 mg/kg)
increased serum C-peptide level to 768.7%, 367.7%, 586.6%
of diabetic control after 2 h, 1 week, 2 weeks of daily drug
administration respectively.
Vinp (10 mg/kg) signiﬁcantly increased serum C-peptide
level to 933.6, 490, 684.3% of diabetic control after 2 h,
Table 10 Effect of Glcl, Sild and Vinp individually on wet LGC of STZ-induced diabetic rats after 2 weeks of daily drug
administration.
Drugs and doses Parameters
Liver glycogen content
Absolute value €X± S.E. (mg/g wet liver) % of diabetic control
Normal control (citrate buﬀer) 127.9 ± 8.435 963.1
Diabetic control (streptozotocin 50 mg/kg, I.P.) * 13.28 ± 1.795 100
Gliclazide (10 mg/kg, I.P.) *a 88.32 ± 10.95 665.06
Sildenaﬁl (5 mg/kg, I.P.) *ab 53.02 ± 3.899 399.24
Sildenaﬁl (10 mg/kg, I.P.) *ab 57.36 ± 3.735 431.92
Sildenaﬁl (20 mg/kg, I.P.) *a 66.12 ± 7.188 497.89
Vinpocetine (10 mg/kg, I.P.) *ac 72.51 ± 4.448 546
Vinpocetine (20 mg/kg, I.P.) *ac 65.18 ± 9.063 490.81
Vinpocetine (40 mg/kg, I.P.) *abc 40.59 ± 2.336 305.64
The number of animals in each group ranges between 6 and 8.
Data were expressed as mean ± S.E.
Statistical analysis was carried out by one way ANOVA followed by Post-test Newman–Keuls multiple comparison test.
* Signiﬁcantly different from normal control at P< 0.05.
a Signiﬁcantly different from diabetic control at P< 0.05.
b Signiﬁcantly different from gliclazide at P < 0.05.
c Signiﬁcantly different from sildenaﬁl (20 mg/kg) at P< 0.05.
Figure 1 Effect of Glcl, Sild and Vinp individually on SBG level
of STZ-induced diabetic rats after 2 h of drug administration. The
number of animals in each group ranges between 6 and 8. Data
were expressed as mean ± S.E. Statistical analysis was carried out
by one way ANOVA followed by Post-test Newman–Keuls
multiple comparison test. *Signiﬁcantly different from normal
control at P< 0.05. aSigniﬁcantly different from diabetic control
at P< 0.05. bSigniﬁcantly different from gliclazide at P< 0.05.
cSigniﬁcantly different from sildenaﬁl (20 mg/kg) at P< 0.05.
Figure 2 Effect of Glcl, Sild and Vinp individually on SBG level
of STZ-induced diabetic rats after 1 week of daily drug adminis-
tration. The number of animals in each group ranges between 6
and 8. Data were expressed as mean ± S.E. Statistical analysis
was carried out by one way ANOVA followed by Post-test
Newman–Keuls multiple comparison test. *Signiﬁcantly different
from normal control at P< 0.05. aSigniﬁcantly different from
diabetic control at P< 0.05. bSigniﬁcantly different from glicla-
zide at P< 0.05. cSigniﬁcantly different from sildenaﬁl (20 mg/kg)
at P< 0.05.
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Moderate dose of Vinp (20 mg/kg) signiﬁcantly elevated serum
C-peptide level to 1197.6, 593.6, 792% of diabetic control after
2 h, 1 week, 2 weeks of daily drug administration respectively.
The highest dose of Vinp (40 mg/kg) signiﬁcantly raised serum
C-peptide level to 2021.6%, 753.1%, 1003.4% of diabetic con-
trol after 2 h, 1 week, 2 weeks of daily drug administration
respectively (Fig. 3).3.4. Effect of Glcl, Sild or Vinp on LGC of STZ-induced diabetic
rats after 2 weeks of daily drug administration
STZ signiﬁcantly lowered liver glycogen content to 10% of the
normal control value. Glcl (10 mg/kg) signiﬁcantly raised LGC
to 665% of diabetic control. As well as, Sild (5, 10, 20 mg/kg)
Figure 3 Effect of Glcl, Sild and Vinp individually on SBG level
of STZ-induced diabetic rats after 2 weeks of daily drug admin-
istration. The number of animals in each group ranges between 6
and 8. Data were expressed as mean ± S.E. Statistical analysis
was carried out by one way ANOVA followed by Post-test
Newman–Keuls multiple comparison test. *Signiﬁcantly different
from normal control at P< 0.05. aSigniﬁcantly different from
diabetic control at P< 0.05. bSigniﬁcantly different from glicla-
zide at P< 0.05. cSigniﬁcantly different from sildenaﬁl (20 mg/kg)
at P< 0.05.
Figure 4 Effect of Glcl, Sild and Vinp individually on serum
insulin level of STZ-induced diabetic rats after two hours of drug
administration. The number of animals in each group ranges
between 6 and 8. Data were expressed as mean ± S.E. Statistical
analysis was carried out by one way ANOVA followed by Post-
test Newman–Keuls multiple comparison test. *Signiﬁcantly
different from normal control at P< 0.05. aSigniﬁcantly different
from diabetic control at P< 0.05. bSigniﬁcantly different from
gliclazide at P< 0.05. cSigniﬁcantly different from sildenaﬁl
(20 mg/kg) at P< 0.0.5.
Figure 5 Effect of Glcl, Sild and Vinp individually on serum
insulin level of STZ-induced diabetic rats after one week of daily
drug administration. The number of animals in each group ranges
between 6 and 8. Data were expressed as mean ± S.E. Statistical
analysis was carried out by one way ANOVA followed by Post-
test Newman–Keuls multiple comparison test. *Signiﬁcantly
different from normal control at P< 0.05. aSigniﬁcantly different
from diabetic control at P< 0.05. bSigniﬁcantly different from
gliclazide at P< 0.05. cSigniﬁcantly different from sildenaﬁl
(20 mg/kg) at P< 0.05.
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431.9%, 497.9% of diabetic control respectively in a dose
dependant manner. On the other hand, Vinp (10, 20, 40 mg/
kg) signiﬁcantly raised liver glycogen content to 546%,
490.8%, 305.6% of diabetic control respectively (Fig. 4).4. Discussion
Diabetes mellitus is a chronic disease and affects many patients
worldwide. Complications of diabetes comprise hyperlipopro-
teinemia, myocardial disease, diabetic foot and kidney disease.
It is of importance to screen substances with the hope of being
effective in diabetes mellitus with more efﬁcacy and safety.
Vinp is an alkaloid derivative of vincamine22 which inhibits
selectively PDE123 and is characterized by having antioxidant
activity.24 Sild is a selective inhibitor of PDE5 and is also char-
acterized by antioxidant activity25 (Figs. 5–10).
To investigate the antidiabetic effects of Vinp and Sild,
blood glucose level is determined in the current study. The
level of blood glucose is correlated primarily to insulin level
and hepatic glucose metabolizing enzymes. So serum blood
glucose, serum insulin, serum C-peptide levels and liver glyco-
gen are determined for 2 weeks.
Results of the present study revealed that Sild (10, 20 mg/
kg) signiﬁcantly lowered SBG level starting from 2 h after
the ﬁrst dose and continued its hypoglycemic effect up to
2 weeks of daily drug administration. These data are in accor-
dance with previous results of Abdollahi, who demonstrated
that Sild lowers blood glucose concentration at higher doses.26
On the other hand, Milani found that Sild (1 mg/kg) did
not lower hyperglycemia in male wistar albino rats starting
from the ﬁrst day and continued up to 15 days.27 The differ-
ence in the results could be due to the difference in doses.
The mechanism of hypoglycemia induced by Sild could be
produced via increased insulin secretion parallel to its hypogly-
cemic effect. Sild (5, 10, and 20 mg/kg) signiﬁcantly increased
the synthesis of insulin as evidenced by the increase in serum
Figure 6 Effect of Glcl, Sild and Vinp individually on serum
insulin level of STZ-induced diabetic rats after two weeks of daily
drug administration. The number of animals in each group ranges
between 6 and 8. Data were expressed as mean ± S.E. Statistical
analysis was carried out by one way ANOVA followed by Post-
test Newman–Keuls multiple comparison test. *Signiﬁcantly
different from normal control at P< 0.05. aSigniﬁcantly different
from diabetic control at P< 0.05. bSigniﬁcantly different from
gliclazide at P< 0.05. cSigniﬁcantly different from sildenaﬁl
(20 mg/kg) at P< 0.05.
Figure 7 Effect of Glcl, Sild and Vinp individually on serum C-
peptide level of STZ-induced diabetic rats after 2 h of drug
administration. The number of animals in each group ranges
between 6 and 8. Data were expressed as mean ± S.E. Statistical
analysis was carried out by one way ANOVA followed by Post-
test Newman–Keuls multiple comparison test. *Signiﬁcantly
different from normal control at P< 0.05. aSigniﬁcantly different
from diabetic control at P< 0.05. bSigniﬁcantly different from
gliclazide at P< 0.05. cSigniﬁcantly different from sildenaﬁl
(20 mg/kg) at P< 0.05.
Figure 8 Effect of Glcl, Sild and Vinp individually on serum C-
peptide level of STZ-induced diabetic rats after 1 week of daily
drug administration. The number of animals in each group ranges
between 6 and 8. Data were expressed as mean ± S.E. Statistical
analysis was carried out by one way ANOVA followed by Post-
test Newman–Keuls multiple comparison test. *Signiﬁcantly
different from normal control at P< 0.05. aSigniﬁcantly different
from diabetic control at P< 0.05. bSigniﬁcantly different from
gliclazide at P< 0.05. cSigniﬁcantly different from sildenaﬁl
(20 mg/kg) at P< 0.05.
Figure 9 Effect of Glcl, Sild and Vinp individually on serum C-
peptide level of STZ-induced diabetic rats after 2 weeks of daily
drug administration. The number of animals in each group ranges
between 6 and 8. Data were expressed as mean ± S.E. Statistical
analysis was carried out by one way ANOVA followed by Post-
test Newman–Keuls multiple comparison test. *Signiﬁcantly
different from normal control at P< 0.05. aSigniﬁcantly different
from diabetic control at P< 0.05. bSigniﬁcantly different from
gliclazide at P< 0.05. cSigniﬁcantly different from sildenaﬁl
(20 mg/kg) at P< 0.05.
Beneﬁcial effects of phosphodiesterase inhibitors on diabetes mellitus in rats 187
Figure 10 Effect of Glcl, Sild and Vinp individually on wet LGC
of STZ-induced diabetic rats after two weeks of daily drug
administration. The number of animals in each group ranges
between 6 and 8. Data were expressed as mean ± S.E. Statistical
analysis was carried out by one way ANOVA followed by Post-
test Newman–Keuls multiple comparison test. *Signiﬁcantly
different from normal control at P< 0.05. aSigniﬁcantly different
from diabetic control at P< 0.05. bSigniﬁcantly different from
gliclazide at P< 0.05. cSigniﬁcantly different from sildenaﬁl
(20 mg/kg) at P< 0.05.
188 M.E.S. El Sayed et al.C-peptide level. Moreover, the hypoglycemic effect of Sild is
related to increase in LGC where SBG is converted to hepatic
glycogen. Effects of Sild on LGC were in agreement with those
reported by Abdollahi who found that Sild administration
markedly reduces liver glycogenolysis.26
Vinp (10, 20, and 40 mg/kg) signiﬁcantly increased serum
insulin level starting from 2 h after the ﬁrst dose and continued
its insulinotropic action up to two weeks of daily drug
administration.
These results are in agreement with the data published by
Han, who demonstrated that 8-methoxymethyl-isobutylmeth-
ylxanthine (8MM-IBMX) a selective PDE1 inhibitor signiﬁ-
cantly increased glucose-induced insulin secretion from
pancreatic islets.28 Also, Heimann et al., proved the presence
of PDE1 in human and rat pancreatic islets and their inhibi-
tion potentiates glucose-stimulated insulin secretion.29
On the other hand, our data are not in agreement with the
results obtained by Shaﬁee-Nick who found that zaprinast
(PDE1/PDE5 inhibitor) did not modify glucose-induced insu-
lin release from pancreatic islets.30 The discrepancy in the
results may be due to the potent inhibition of zaprinast to
PDE5 compared with PDE1 as rationalized by Ahmad et al.31
Therefore, the hypoglycemic action of Vinp could be attrib-
uted to the increase in serum insulin level and the increase in
serum C-peptide level. Vinp increases the synthesis of insulin
as reported by the increase in serum C-peptide level. The hypo-
glycemic effect of Vinp could be produced via the increase in
LGC where serum glucose is converted to liver glycogen.
Regarding the effect of Vinp on LGC, limited data are
available in the literature. However, Vinp showed antioxidant
activity against oxidative stress induced in hepatic
ischemia–reperfusion (IR) injury.15
In the present study, Glcl signiﬁcantly lowered SBG level
starting from 2 h after the ﬁrst dose and continued thehypoglycemic action up to two weeks of daily drug administra-
tion. These data are in accordance with Hong et al.32
The hypoglycemic action of Glcl could be due to insulino-
tropic effect of Glcl accompanied by parallel increase in C-pep-
tide level. These ﬁndings were supported by Juhl et al.33
LGC was signiﬁcantly improved after 2 weeks of daily
administration of Glcl in diabetic rats which demonstrate the
extrapancreatic action of Glcl. These data are in consistence
with those recorded by Sivakumar.34
5. Conclusion
The study established the possible anti-diabetic effect of Vinp
and Sild which is accomplished through pancreatic and extra-
pancreatic actions. The study conﬁrmed the hypothesis that,
cGMP and cAMP may have a role in the augmentation of
insulin secretion.35,36
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None declared.
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